Entrada Therapeutics/TRDA

2.2%
-
1D1W1MYTD1YMAX

About Entrada Therapeutics

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Ticker

TRDA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Dipal Doshi

Employees

160

Headquarters

Boston, United States

TRDA Metrics

BasicAdvanced
US$506M
Market cap
23.90
P/E ratio
US$0.63
EPS
-
Beta
-
Dividend rate
US$506M
US$18.44
US$10.62
79K
2.381
8.118
4.76%
9.41%
7.06%
23.898
3.107
1.87
1.879
544.79%
124.73%

What the Analysts think about TRDA

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 2 analysts.
46.87% upside
High US$25.00
Low US$20.00
US$15.32
Current price
US$22.50
Average price target

TRDA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
39.59% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$59M
41.39%
Net income
US$23M
-346.32%
Profit margin
39.59%
-274.25%

TRDA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 214.48%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-US$0.78
US$1.02
-US$0.29
US$0.68
-
Expected
-US$0.69
-US$0.74
-US$0.17
-US$0.59
US$0.14
Surprise
13.04%
-238.63%
72.62%
-214.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Entrada Therapeutics stock?

Entrada Therapeutics (TRDA) has a market cap of $506M as of May 20, 2024.

What is the P/E ratio for Entrada Therapeutics stock?

The price to earnings (P/E) ratio for Entrada Therapeutics (TRDA) stock is 23.9 as of May 20, 2024.

Does Entrada Therapeutics stock pay dividends?

No, Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Entrada Therapeutics dividend payment date?

Entrada Therapeutics (TRDA) stock does not pay dividends to its shareholders.

What is the beta indicator for Entrada Therapeutics?

Entrada Therapeutics (TRDA) does not currently have a Beta indicator.

What is the Entrada Therapeutics stock price target?

The target price for Entrada Therapeutics (TRDA) stock is $22.5, which is 46.87% above the current price of $15.32. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Entrada Therapeutics stock

Buy or sell Entrada Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing